530 T-cell immunoglobulin– and mucin domain–containing (TIM)–3 downregulation in response to ex vivo activation and cancer targets correlates to NK cell functionality

530 T-cell immunoglobulin– and mucin domain–containing (TIM)–3 downregulation in response to ex vivo activation and cancer targets correlates to NK cell functionality

Bibliographic Details
Main Authors:	Tram Dao, Sagar Utturkar, Nadia Lanman
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2020-11-01
Series:	Journal for ImmunoTherapy of Cancer

Similar Items

TIM-3 Expression Is Downregulated on Human NK Cells in Response to Cancer Targets in Synergy with Activation
by: Tram N. Dao, et al.
Published: (2020-08-01)

Producing Recombinant HEK293 T-cells with High Expression of T-cell Immunoglobulin and Mucin Domain-3 (Tim3) Protein
by: Mona Moballegh-Naseri, et al.
Published: (2015-03-01)

Association of T-cell immunoglobulin and mucin domain-containing molecule 3 (Tim-3) polymorphisms with susceptibility and disease progression of HBV infection.
by: Jingyu Liao, et al.
Published: (2014-01-01)

Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
by: Vida Homayouni, et al.
Published: (2016-11-01)

Regulation of Th1 T Cell Differentiation by Iron via Upregulation of T Cell Immunoglobulin and Mucin Containing Protein-3 (TIM-3)
by: Christa Pfeifhofer-Obermair, et al.
Published: (2021-05-01)

Inhibition of T cell immunoglobulin and mucin-1 (TIM-1) protects against cerebral ischemia-reperfusion injury
by: Yueying Zheng, et al.
Published: (2019-08-01)

Altered expression of T cell Immunoglobulin-Mucin (TIM) molecules in bronchoalveolar lavage CD4<sup>+ </sup>T cells in sarcoidosis
by: Olsson Tomas, et al.
Published: (2009-05-01)

Correction to: Inhibition of T cell immunoglobulin and mucin-1 (TIM-1) protects against cerebral ischemia-reperfusion injury
by: Yueying Zheng, et al.
Published: (2019-09-01)

Evaluating T-Cell Immunoglobulin Mucin-3 (TIM-3) Receptor in the Growth Inhibition of Acute Lymphoblastic Leukemia (ALL) Cell Lines
by: Narges Zargar-Balajam, et al.
Published: (2015-10-01)

T cell immunoglobulin domain and mucin domain-3 as an emerging target for immunotherapy in cancer management
by: Yoneda A, et al.
Published: (2013-11-01)

Serum Levels of T Cell Immunoglobulin and Mucin-Domain Containing Molecule 3 in Patients with Systemic Lupus Erythematosus
by: Tomoyuki Asano, et al.
Published: (2020-11-01)

Association of soluble T cell immunoglobulin domain and mucin-3 (sTIM-3) and mac-2 binding protein glycosylation isomer (M2BPGi) in patients with autoimmune hepatitis.
by: Kiyoshi Migita, et al.
Published: (2020-01-01)

Knockdown of T Cell Immunoglobulin and Mucin 1 (Tim-1) Suppresses Glioma Progression Through Inhibition of the Cytokine-PI3K/AKT Pathway
by: Zhou P, et al.
Published: (2020-08-01)

Tim-3 associated with apoptotic NK cells and disease activity in SLE
by: Di Zhao, et al.
Published: (2021-03-01)

Expression and significance of programmed death-1 and T-cell immunoglobulin- and mucin domain-3-containing molecule 3 in hepatocellular carcinoma
by: ZHOU Ge
Published: (2020-11-01)

Effect of TIM-3 Blockade on the Immunophenotype and Cytokine Profile of Murine Uterine NK Cells.
by: Sudipta Tripathi, et al.
Published: (2015-01-01)

Fine Particulate Matter-Induced Exacerbation of Allergic Asthma via Activation of T-cell Immunoglobulin and Mucin Domain 1
by: Yun-Xia Zhao, et al.
Published: (2018-01-01)

TIGIT+ TIM-3+ NK cells are correlated with NK cell exhaustion and disease progression in patients with hepatitis B virus‑related hepatocellular carcinoma
by: Lihua Yu, et al.
Published: (2021-01-01)

Association between Gene Polymorphisms of T Cell Immunoglobulin Domain and Mucin Domain-3 and Risk of Asthma: A Systematic Review and Meta-analysis
by: Wenping Wei, et al.
Published: (2021-02-01)

Mechanism of gamma-chain cytokines in regulating the expression of T-cell immunoglobulin and mucin domain-containing molecule 3 in CD8+ T cells of chronic hepatitis B patients
by: YANG Xiaofei
Published: (2021-05-01)

Oridonin Could Inhibit Inflammation and T-cell Immunoglobulin and Mucin-3/Galectin-9 (TIM-3/Gal-9) Autocrine Loop in the Acute Myeloid Leukemia Cell Line (U937) as Compared to Doxorubicin
by: Farzad Nasri, et al.
Published: (2020-12-01)

Tim-3 Is Upregulated in NK Cells during Early Pregnancy and Inhibits NK Cytotoxicity toward Trophoblast in Galectin-9 Dependent Pathway.
by: Jintang Sun, et al.
Published: (2016-01-01)

The Role of T Cell Immunoglobulin Mucin Domains 1 and 4 in a Herpes Simplex Virus-Induced Behçet’s Disease Mouse Model
by: Ju A. Shim, et al.
Published: (2013-01-01)

The Role of Tim-3 on dNK Cells Dysfunction During Abnormal Pregnancy With Toxoplasma gondii Infection
by: Teng Li, et al.
Published: (2021-02-01)

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
by: Jana Rakova, et al.
Published: (2021-01-01)

Workshops [pp. 357-530]
by: Hystrix Editor
Published: (2008-05-01)

Study of T-cell immunoglobulin and mucin domain-3 expression profile in peripheral blood and bone marrow of human acute lymphoblastic leukemia patients
by: Narges Zargar Balajam, et al.
Published: (2020-01-01)

Peripheral blood TIM-3 positive NK and CD8+ T cells throughout pregnancy: TIM-3/galectin-9 interaction and its possible role during pregnancy.
by: Matyas Meggyes, et al.
Published: (2014-01-01)

Memory Regulatory T cells Increase Only In Inflammatory Phase of Chronic Hepatitis B Infection and Related to Galectin-9/T-cell Immunoglobulin and Mucin Domain-3 interaction
by: Ching Chih Hu, et al.
Published: (2018)

Blocking TIM-3 reinvigorates exhausted CD8 T cells with no impact on NK cell function in ART-treated HIV-infected patients
by: C. Gutiérrez, et al.
Published: (2019-12-01)

The Emerging Role of T-Cell Immunoglobulin Mucin-3 in Breast Cancer: A Promising Target For Immunotherapy
by: Yizi Cong, et al.
Published: (2021-08-01)

IL-15, TIM-3 and NK cells subsets predict responsiveness to anti-CTLA-4 treatment in melanoma patients
by: Rossana Tallerico, et al.
Published: (2017-02-01)

NANOG helps cancer cells escape NK cell attack by downregulating ICAM1 during tumorigenesis
by: Kotaro Saga, et al.
Published: (2019-10-01)

Downregulation of MCT4 for lactate exchange promotes the cytotoxicity of NK cells in breast carcinoma
by: Yaping Long, et al.
Published: (2018-09-01)

Can selective MHC downregulation explain the specificity and genetic diversity of NK cell receptors?
by: Paola eCarrillo-Bustamante, et al.
Published: (2015-06-01)

OPTIMIZING INTRACELLULAR SIGNALING DOMAINS FOR CAR-NK CELLS
by: J.T.C. Azevedo, et al.
Published: (2020-11-01)

Expression patterns of killer cell immunoglobulin-like receptors (KIR) of NK-cell and T-cell subsets in Old World monkeys.
by: Meike Hermes, et al.
Published: (2013-01-01)

The inhibitory receptor Tim-3 fails to suppress IFN-γ production via the NFAT pathway in NK-cell, unlike that in CD4+ T cells
by: Xiaowen Yu, et al.
Published: (2021-04-01)

Commentary: Can selective MHC downregulation explain the specificity and genetic diversity of NK cell receptors?
by: Philippe Auguste ROBERT, et al.
Published: (2015-08-01)

Impact of MUC1 mucin downregulation in the phenotypic characteristics of MKN45 gastric carcinoma cell line.
by: Natália R Costa, et al.
Published: (2011-01-01)